Formulation of GCC agonist for use in the treatment or prevention of a gastrointestinal disease or disorder in a subject in need that comprises: (1) a nucleus, which contains at least one GCC agonist peptide selected from the group consisting of SEQ ID NO: 1-44 and 99-107； I either (2) (i) one or more pH-dependent polymers that degrade in a pH range of 4.5 to 5.5, in which the formulation is optimized for administration of the GCC agonist to the duodenum or jejunum , or (2) (ii) one or more pH-dependent polymers that degrade in a pH range of 5.5 to 6.5 or in a pH range of 6.5 to 7.5, in which The formulation is optimized for the administration of the GCC agonist to the ileum, terminal ileum or ascending colon； and optionally (3) an inflatable polymer, and / or a degradable composition in which when the formulation is optimized for the administration of the GCC agonist to the duodenum or jejunum the gastrointestinal disease or disorder is selected from irritable bowel syndrome, non-ulcer dyspepsia , chronic intestinal pseudo-obstruction, functional dyspepsia, colonic pseudo-obstruction, duodenogastric reflux, gastroesophageal reflux disease, chronic idiopathic constipation, gastroparesis, heartburn, gastric cancer and H. pilori infection, and when the formulation is optimized for administration of the GCC agonist at ileum, terminal ileum or ascending colon the gastrointestinal disease or disorder is selected from ileitis (postoperative ileitis), Crohn's disease, ulcerative colitis, terminal ileitis and colon cancer.Formulación de agonista de GCC para su uso en el tratamiento o la prevención de una enfermedad o trastorno gastrointestinal en un sujeto que lo necesita que comprende: (1) un núcleo, que contiene al menos un péptido agonista de GCC seleccionado del grupo que consiste en SEQ ID NO: 1-44 y 99-107； y o bien (2)(i) uno o más polímeros dependientes del pH que se degradan en un intervalo de pH de 4,5 a 5,5, en la que la formulación está optimizada para la admini
